John Bertrand, CEO of Digital Diagnostics, leads the development of LumineticsCore, an innovative diabetic retinopathy diagnostic algorithm that operates without physician involvement. His approach emphasizes close collaboration with end-users and stakeholders to refine the product and navigate regulatory and reimbursement challenges, demonstrating the importance of genuine engagement and relationship-building in successfully launching disruptive healthcare technologies.
A Guide to Widespread Therapy Adoption in Medtech